Our results suggest a mechanistic justification for this hypothesis: lowering GRK2 activity alongside β1-AR inhibition reduces the amplitude of cAMP overshoot, and partially rescues the dynamic range of cAMP concentration compared with β-blockers alone in heart failure conditions. Here, GRK2 is linked to heart failure.